Login / Signup

Population pharmacokinetics of intravenous and oral ciprofloxacin in children to optimize dosing regimens.

Déborah HirtM OualhaB PasquiersS BlanotR RubinstazjnC GlorionS El MessaoudiD DrummondV LopezJ ToubianaA BérangerSana BoujaafarYi ZhengCarmen CapitoS WinterP L LégerR BerthaudInès GanaF FoissacJ M TréluyerN BouazzaS Benaboud
Published in: European journal of clinical pharmacology (2021)
The recommended IV dose of 10 mg/kg q8h, not exceeding 400 mg q8h, would achieve AUC0-24 h to successfully treat bacteria with MICs ≤ 0.25 (e.g. Salmonella, Escherichia coli, Proteus, Haemophilus, Enterobacter, and Klebsiella). A dose increase to 600 mg q8h in children > 40 kg and to 15 mg/kg q8h (max 400 mg q8h, max 600 mg q8h if augmented renal clearance, i.e., eGFR > 200 mL/min/1.73 m2) in children < 40 kg would be needed for the strains with highest MIC (16% of Pseudomonas aeruginosa and 47% of Staphylococcus aureus). The oral recommended dose of 20 mg/kg q12h (not exceeding 750 mg) would cover bacteria with MICs ≤ 0.125 but may be insufficient for bacteria with higher MIC and a dose increase according bodyweight and eGFR would be needed. These doses should be prospectively confirmed, and a therapeutic drug monitoring could be used to refine them individually.
Keyphrases
  • escherichia coli
  • pseudomonas aeruginosa
  • staphylococcus aureus
  • small cell lung cancer
  • young adults
  • biofilm formation
  • cystic fibrosis
  • high dose
  • acinetobacter baumannii